Published in AIDS Weekly, February 17th, 1997
Abelcet is a proprietary antifungal agent developed by The Liposome Company, Princeton, New Jersey. Fourteen countries have approved Abelcet for the treatment of various severe systemic fungal infections. Abelcet was previously approved in October 1995 in Spain for the second-line treatment of systemic fungal infections.
Spain has joined the United Kingdom, Italy, Ireland, Denmark, and Austria as countries that have approved Abelcet as first-line therapy for candidiasis. Greece has approved Abelcet for first-line...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.